The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | The impact of different treatment regimens on the outcomes of patients with CLL with del(11q)
Thomas Kipps, MD, PhD, UC San Diego Moores Cancer Center, La Jolla, CA, comments on the outcomes of patients with chronic lymphocytic leukemia (CLL) with del(11q) treated with ibrutinib, chemotherapy, and chemoimmunotherapy, highlighting the results from RESONATE (NCT01578707) evaluating ibrutinib monotherapy in relapsed/refractory (R/R) patients and RESONATE-2 (NCT01722487) comparing ibrutinib and chlorambucil in treatment-naive patients. Whilst RESONATE reported worse outcomes for patients with del(11q), RESONATE-2 showed improved outcomes in this patient population. Dr Kipps explains that a recent study showed that patients with del(11q) acquired more cytogenetic changes with chemotherapy. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
AbbVie: Consultancy, Research Funding; Genentech-Roch: Consultancy, Research Funding; Gilead: Consultancy; Pharmacyclics, LLC an AbbVie Company: Consultancy, Research Funding; Celgene: Consultancy; Oncternal: Research Funding.
